Chapel Hill biotech gets FDA green light to test heart disease therapy

A Chapel Hill biotech heard good news from the U.S. Food and Drug Administration on Friday. The regulatory body accepted an investigational new drug (IND) application from NanoCor Therapeutics, Inc. relating to Carfostin, an experimental cardiac gene therapy in development for the treatment of congestive heart failure (CHF). Simply accepting the application is still a long way from approving a finished drug, of course, but is seen as an important milestone for drug developers. Now, NanoCor may…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news